002437.SZ SHZ
Harbin Gloria Pharmaceuticals Co., Ltd
1W: -3.4%
1M: -16.5%
3M: +24.1%
YTD: +4.9%
1Y: +2.8%
3Y: +78.9%
5Y: +43.1%
¥3.65 ($0.54)
+0.18 (+5.19%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$2.4B
-7.1% ▼
5Y CAGR: -13.5%
Gross Profit
$1.3B
-14.7% ▼
5Y CAGR: -18.8%
Operating Income
$285M
+62.7% ▲
5Y CAGR: -2.3%
Net Income
$233M
+93.4% ▲
EPS (Diluted)
$0.10
+82.8% ▲
EBITDA
$385M
+19.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $3.1B | $3.1B | $3.1B | $2.6B | $2.4B |
| YoY Growth | -39.6% | +3.0% | -1.2% | -15.5% | -7.1% |
| Cost of Revenue | $793M | $830M | $719M | $1.1B | $1.1B |
| Gross Profit | $2.3B | $2.3B | $2.4B | $1.5B | $1.3B |
| Gross Margin | 74.0% | 73.6% | 76.9% | 58.3% | 53.5% |
| R&D Expenses | $125M | $98M | $101M | $85M | $91M |
| SG&A Expenses | $2.1B | $2.0B | $2.1B | $1.2B | $944M |
| Operating Expenses | $2.3B | $2.1B | $2.3B | $1.4B | $1.0B |
| Operating Income | $785M | $157M | -$112M | $175M | $285M |
| Operating Margin | 25.7% | 5.0% | -3.6% | 6.7% | 11.7% |
| Interest Expense | $92M | $71M | $81M | $43M | $10M |
| Income Before Tax | $565M | $86M | -$270M | $177M | $284M |
| Tax Expense | $156M | $32M | $20M | $48M | $41M |
| Net Income | $400M | $45M | -$290M | $120M | $233M |
| Net Margin | 13.1% | 1.4% | -9.3% | 4.6% | 9.5% |
| EPS (Diluted) | $0.18 | $0.02 | $-0.13 | $0.05 | $0.10 |
| EBITDA | $819M | $308M | $19M | $324M | $385M |
| Shares Outstanding | 2.20B | 2.20B | 2.20B | 2.20B | 2.26B |